TY - JOUR
T1 - Levels of SARS-COV-2 anti-spike protein receptor-binding domain (S-RBD) IgG in Indonesian-vaccinated healthcare workers
T2 - experimental research
AU - Tambunan, Betty A.
AU - Ugrasena, Dewa I.G.
AU - Nugraha, Jusak
AU - Fitriah, Munawaroh
AU - Permatasari, Cynthia A.
AU - Moses, Emmanuel J.
AU - Yusoff, Narazah M.
AU - Aryati,
N1 - Funding Information:
This study has been reviewed by the Health Research Ethics Committee of Dr. Soetomo General Academic Hospital, Surabaya, Indonesia (0030/KEPK/VII/2020). We acknowledge Mindray Medical Indonesia for kindly supplying reagents without any influence on study design or data analysis. We appreciate all participants for supporting and cooperating with this study. We would like to thank to our editor, 'Fis Citra Ariyanto.'
Publisher Copyright:
© 2023 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.
PY - 2023/4/1
Y1 - 2023/4/1
N2 - Introduction: Studies evaluating the levels of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) anti-spike protein receptor-binding domain (S-RBD) immunoglobulin G (IgG) antibodies in vaccinated healthcare workers in Indonesia are limited. Objectives: Evaluating time-dependent levels of anti-IgG S-RBD antibodies and monitoring the response of healthcare workers in a tertiary hospital in Indonesia after vaccination. Materials and methods: This prospective cohort observational study was conducted from January to December 2021. A total of 50 healthcare workers participated in the study. Blood samples were collected at five time points. Antibody levels were measured using a CL 1000i analyzer (Mindray Bio-Medical Electronics Co., Ltd., Shenzhen, China). Antibody levels between groups were analyzed using the Wilcoxon signed-rank test with P less than 0.05. Results: The median levels of SARS-CoV-2 anti-S-RBD IgG antibody on days 14, 28, 90, and 180 were significantly higher than the levels on day 0 (P < 0.001). After the second dose, peak levels were observed on day 14; the levels decreased gradually after day 28. Despite receiving two doses of the vaccine, 10 out of 50 participants (20%) were infected with COVID-19 (coronavirus disease 2019). However, symptoms were mild, and antibody levels were significantly higher than in noninfected participants (P < 0.001). Conclusion: SARS-CoV-2 anti-S-RBD IgG antibody levels increased significantly until day 14 after the second dose; the levels decreased gradually after day 28. Ten participants (20%) were infected with SARS-CoV-2, with mild symptoms.
AB - Introduction: Studies evaluating the levels of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) anti-spike protein receptor-binding domain (S-RBD) immunoglobulin G (IgG) antibodies in vaccinated healthcare workers in Indonesia are limited. Objectives: Evaluating time-dependent levels of anti-IgG S-RBD antibodies and monitoring the response of healthcare workers in a tertiary hospital in Indonesia after vaccination. Materials and methods: This prospective cohort observational study was conducted from January to December 2021. A total of 50 healthcare workers participated in the study. Blood samples were collected at five time points. Antibody levels were measured using a CL 1000i analyzer (Mindray Bio-Medical Electronics Co., Ltd., Shenzhen, China). Antibody levels between groups were analyzed using the Wilcoxon signed-rank test with P less than 0.05. Results: The median levels of SARS-CoV-2 anti-S-RBD IgG antibody on days 14, 28, 90, and 180 were significantly higher than the levels on day 0 (P < 0.001). After the second dose, peak levels were observed on day 14; the levels decreased gradually after day 28. Despite receiving two doses of the vaccine, 10 out of 50 participants (20%) were infected with COVID-19 (coronavirus disease 2019). However, symptoms were mild, and antibody levels were significantly higher than in noninfected participants (P < 0.001). Conclusion: SARS-CoV-2 anti-S-RBD IgG antibody levels increased significantly until day 14 after the second dose; the levels decreased gradually after day 28. Ten participants (20%) were infected with SARS-CoV-2, with mild symptoms.
KW - CoronaVac vaccine
KW - SARS-CoV-2 anti-spike protein RBD IgG
KW - healthcare workers
KW - infectious disease
UR - http://www.scopus.com/inward/record.url?scp=85161538874&partnerID=8YFLogxK
U2 - 10.1097/MS9.0000000000000425
DO - 10.1097/MS9.0000000000000425
M3 - Article
AN - SCOPUS:85161538874
SN - 2049-0801
VL - 85
SP - 802
EP - 806
JO - Annals of Medicine and Surgery
JF - Annals of Medicine and Surgery
IS - 4
ER -
